Stockwinners Market Radar for June 23, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:25 EDT Myan wins summary judgment ruling in Kansas EpiPen class action - Viatris (VTRS) announced that the "U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's (MYL) favor on the company's summary judgment motion in the class action related to EpiPen(R) Auto-Injector. The company is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers."

18:54 EDT IGC completes final cohort of Phase 1 trial on Alzheimer's patients - India Globalization Capital, Inc. announced it has completed Cohort 3 of its Phase 1 clinical trial on IGC's tetrahydrocannabinol-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer's disease. As previously disclosed, IGC submitted IGC-AD1, its investigational drug candidate for Alzheimer's, to the U.S. Food and Drug Administration under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial, on Alzheimer's patients, from the FDA on July 30, 2020. Cohort 3 is the final cohort in IGC's Alzheimer's Phase 1 trial. The Data and Safety Monitoring Committee for IGC's clinical trial will review the data from Cohort 3, and IGC will report its findings from all three Cohorts to the FDA.

18:44 EDT J.M. Smucker CEO sells 10K shares of common stock - In a regulatory filing, J.M. Smucker disclosed that its CEO Mark Smucker sold 10K shares of common stock on June 21st in a total transaction size of $1.31M, reducing his stake by about 5%.

17:34 EDT Casey's General Stores director Bridgewater sells almost $599K in company shares - Casey's General Stores director Diane Bridgewater sold 3,000 shares of company stock at $199.65 per share on June 21, for a total transaction value of $598,950.

17:27 EDT KB Home raises FY21 housing revenue view to $5.9B-$6.1B from $5.7B-$6.1B - Raises FY21 average selling price to $415,000-$425,000 from $405,000-$415,000. Sees FY21 operating margin 11.5%-12%. Sees FY21 gross profit margin 21.5%-22%. Sees FY21 effective tax rate 20%. Says backlog supports higher revenues the company expects this year.

17:24 EDT KB Home sees Q3 housing revenue $1.5B-$1.58B - Sees Q3 average selling price $420,000. Sees Q3 gross profit margin 21.7%. Says benefitting from solid performance in newer communities. Says profitability per unit grew meaningfully on a sequential basis. Says deliveries were at the low end of the anticipated range. Comments and guidance taken from Q2 earnings conference call.

16:49 EDT FTAC Olympus Acquisition shareholders approve Payoneer business combination - FTAC Olympus Acquisition (FTOC) shareholders voted to approve the proposed business combination with Payoneer at its Extraordinary General Meeting held today, June 23. More than 97.8% of the votes cast at the meeting voted to approve the business combination. Holders of approximately 65.0% of FTOC's issued and outstanding shares cast votes at the Extraordinary General Meeting. The combined company will be named Payoneer Global (PAYO) and its common stock and warrants, is expected to begin trading on the Nasdaq stock market under the ticker symbol "PAYO" and "PAYOW", respectively, subject to the close of the above transaction.

16:39 EDT NYDIG, Q2 to offer bitcoin solutions for financial institutions - NYDIG and Q2 Holdings announced they will collaborate to provide the more than 18.3M registered users on the Q2 platform with the ability to buy, sell and hold bitcoin. "According to a December 2020 study by Cornerstone Advisors, 15 percent of U.S. consumers own Bitcoin or some other form of cryptocurrency," said Jonathan Price, EVP of Emerging Business, Corporate and Business Development, Q2. "The consumer survey also revealed that the majority of these crypto owners would use their banks to invest in cryptocurrency if they had the choice to do so. We are excited to work with NYDIG to enable financial institutions to take advantage of this market opportunity and meet the demands of their account holders."

16:32 EDT Franklin Street announces $50M share repurchase program - CEO George J. Carter states: "We previously announced 2021 disposition guidance in the range of $350M to $450M in aggregate gross proceeds. We continue to intend to use those proceeds primarily for debt reduction. However, we believe that our stock price may at times not be fully reflective of the value of our underlying assets. As a result, we may use a portion of proceeds from those asset sales for share repurchases as market conditions warrant."

16:24 EDT Credicorp CEO Walter Bayly to retire, Gianfranco Ferrari to succeed - Credicorp announced that the board of directors has appointed Gianfranco Ferrari as the new CEO of Credicorp, effective January 2022. Ferrari is now deputy CEO and head of universal banking, the main line of business at Credicorp. Gianfranco Ferrari will succeed Walter Bayly, who decided to retire at the end of 2021 after an extraordinary 28 year career at the group, including the last three years as CEO of Credicorp. Moreover, the board approved the creation of the position of COO from January 2022, to be held by Alejandro Perez-Reyes and who will report to the CEO.

16:18 EDT Intrepid Potash increases potash price $90 per ton, Trio price $35 per ton - Intrepid Potash announced the following increase to its potash and Trio pricing. In response to recent increases in the barge and inland warehouse potash markets, Intrepid increased its potash price by $90 per ton at all locations and for all product grades. Intrepid is now posted at $250 per ton above 2020 summer-fill price levels. Effective June 23, Intrepid increased its Trio price by $35 per ton on all products. Intrepid is now accepting Trio orders for Q3 delivery.

16:15 EDT Motus GI Holdings appoints ImmunityBio VP Sonja Nelson to board - Motus GI (MOTS) announced the appointment of Sonja Nelson to the company's board of directors and as chair of the audit committee. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets. Nelson has accumulated financial, accounting, and public company experience during her time at several biotechnology, pharmaceutical, and consumer health product companies. Nelson is currently serving as the senior VP, finance, of ImmunityBio (IBRX).

16:12 EDT Highwoods Properties sells non-core Tampa property for $43M - Highwoods Properties has sold Preserve VII, a 115,000 square foot single customer building in north Tampa, for $43M. This property is 100% occupied and is projected to generate $2.0 million of annual cash net operating income, including the impact of $0.4M of free rent, and $2.4M of annual GAAP net operating income in 2021. The Company expects to record a non-FFO gain of approximately $22.8M n the second quarter of 2021 in connection with this sale.

16:11 EDT Arcus says Phase 2 ARC-7 study shows 'encouraging' clinical activity - Arcus Biosciences (RCUS) announced that, at the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity when given as an initial treatment to people with metastatic, PD-L1greater than or equal to50% non-small cell lung cancer. The zimberelimab monotherapy arm showed activity similar to that of marketed anti-PD-1 antibodies studied by other companies in this setting. At the time of data cut off, no unexpected safety signals were observed; and the current safety profile for each arm of the study appears to be consistent with known immune checkpoint inhibitors in this setting. All three arms of the ARC-7 trial, and the ongoing ARC-10 Phase 3 registrational study, will continue to enroll as planned; and ARC-7 data will be submitted later this year for presentation at a medical conference. Partner Gilead Sciences (GILD) has an exclusive option to co-develop and co-commercialize domvanalimab and is anticipated to make a decision regarding opting into the anti-TIGIT program later this year. Arcus and Gilead will continue preparations for additional Phase 3 studies of domvanalimab-based combinations and explore development plans for combinations including domvanalimab and etrumadenant. "This analysis of the dataset for the ongoing ARC-7 study revealed encouraging clinical activity for the anti-TIGIT domvanalimab-based combinations, and furthermore, that the anti-PD-1 zimberelimab monotherapy arm showed activity similar to that of marketed anti-PD-1 antibodies studied in this setting," said Bill Grossman, M.D., Ph.D., Chief Medical Officer of Arcus. "Next steps are to complete enrollment in all our open domvanalimab studies, execute on our broader plans for Phase 3 studies for domvanalimab across multiple cancer types, and further explore combinations with domvanalimab and etrumadenant."

16:08 EDT John McAfee found dead in prison after extradition approval - John McAfee, founder of McAfee Associates in 1984, was found dead in his prison cell in Barcelona, Spain shortly after Spain's National Court approved his extradition to the United States to face criminal tax evasion charges, Reuters and the Associated Press report.

16:07 EDT Blue Hat Interactive receives Nasdaq listing deficiency notification - Blue Hat Interactive has received a notification letter from Nasdaq notifying the company that it is not in compliance with the minimum bid price requirements which require that the closing bid price for the company's ordinary shares listed on Nasdaq be maintained at a minimum of $1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. The company has a period of 180 calendar days from the date of notification, or until December 15, to regain compliance with the minimum bid price requirement. In the event the company does not regain compliance by December 15, 2021, the Company may be eligible for additional time to regain compliance or may be delisted from Nasdaq. The company intends to monitor the closing bid price of its ordinary shares between now and December 15, 2021. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements at the end of the first compliance period, the company's board will consider options that may be available to achieve compliance.

16:04 EDT Rubius Therapeutics doses 1st patient with RTX-240 in Keytruda combo - Rubius Therapeutics announced that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with KEYTRUDA or pembrolizumab for the treatment of patients with relapsed/refractory or locally advanced solid tumors. To be eligible for the trial, patients must have disease that is relapsed or refractory to an anti-PD-1 or PD-L1 therapy. "RTX-240 is designed to activate and expand a patient's own immune cells to mount a broad and potent anti-tumor response. Combining an immune agonist with a PD-1 checkpoint inhibitor has the potential to prevent the cancer from evading the immune response. The RTX-240 and pembrolizumab combination is anticipated to drive activated T cells and NK cells into the tumor microenvironment with the potential to overcome resistance to PD-1 inhibition," said Christina Coughlin, M.D., Ph.D., chief medical officer at Rubius Therapeutics. "Given the favorable emerging safety profile and promising initial clinical activity reported as part of our initial clinical results from the ongoing Phase 1 monotherapy trial of RTX-240 in advanced solid tumors, we believe that the combination with pembrolizumab has the potential to provide significant benefit to patients with disease that is relapsed or refractory to prior anti-PD-1 or PD-L1 therapy."

15:09 EDT Comcast says Peacock to stream Tokyo Olympics coverage live - Comcast's Peacock announced it will launch a Tokyo Olympics destination on July 15, featuring live coverage of "some the Games' biggest events, including gymnastics, track & field, and the US Men's Basketball Team's pursuit of their fourth straight gold." In addition, Peacock will feature new daily live shows, original programming, Olympics channels, full event replays and curated highlights of NBC Olympics' coverage. All of Peacock's Tokyo Olympics programming will be available to stream for free, with exception of USA Men's Basketball live coverage that will be available to Peacock Premium subscribers. Reference Link

14:53 EDT ViacomCBS, Roku up after WSJ discusses possible Comcast deal consideration - Shares of ViacomCBS (VIAC) are up nearly 3% to $41.98 and Roku (ROKU) is up about 5% to $423.07 after The Wall Street Journal's Lillian Rizzo reported that Comcast's (CMCSA) CEO, Brian Roberts is said to be "scoping out" the two as possilbe M&A deal options.

14:19 EDT FHFA's Calabria 'respects' Supreme Court decision, wishes successor 'best' - FHFA Director Mark Calabria's issued a statement on the U.S. Supreme Court's Collins v. Yellen decision, stating in part: "I respect the Supreme Court's decision and the authority of the President to remove the Federal Housing Finance Agency Director. It has been the honor of a lifetime to serve as Director of the Federal Housing Finance Agency alongside world-class staff. During my tenure, FHFA has fulfilled its mission as the economy fluctuated from record-low unemployment and a strong housing market, to a pandemic-triggered recession that spared house prices but contracted supply... However, much work remains. When the housing markets experience a significant downturn, Fannie Mae and Freddie Mac will fail at their current capital levels. I wish my successor all the best in fixing the remaining flaws of the housing finance system in order to preserve homeownership opportunities for all Americans." Reference Link

13:48 EDT Cowen Group up 8% to $43.94 in afternoon trading - At time of writing, Cowen shares are up $3.40, or 8%, to $43.90. Yesterday morning, Cowen announced that its board had approved an increase in the company's existing share repurchase program. With this increase, the total amount now available for repurchase under the current plan is $50M.

13:25 EDT Siemens Healthineers to buy back up to EUR170M in shares - Siemens Healthineers announced that the share buyback resolved on June 21, 2021 by the managing board of Siemens Healthineers will commence on June 28, 2021. In the time period until January 28, 2022, treasury shares of the company with a maximum value of EUR 170M, excluding incidental transaction charges, shall be acquired, in total, however, no more than 6M no-par-value shares. The acquired shares will be used in connection with share-based remuneration programs and, respectively, employee stock programs of the company or affiliated entities of the company and will be delivered to persons who have or had an employment relationship with the company or an affiliated entity of the company, as well as to board members of affiliated entities of the company.

13:05 EDT Establishment Labs breaks ground on third facility in Costa Rica - Establishment Labs held the groundbreaking ceremony for its new SulayIom Innovation Campus in Costa Rica. When complete, the new facilities will total approximately 145,000 square feet and will support the company's continued global growth with additional capacity and capabilities in manufacturing, R&D, digital media, training, and medical education. The new campus will be completed in two phases with the first phase expected to cost approximately $35M, the majority of which the company intends to finance with a local credit partner. Construction on the new building will begin following finalization and execution of certain contractual arrangements. The new facilities will add up to 1,000 new jobs over the next several years and will be located in the Coyol Free Zone in Costa Rica.

12:33 EDT STMicroelectronics announces completion of $750M share buy-back program - STMicroelectronics announces the completion of the share buy-back program of $750M. The buy back was launched on November 5, 2018 and its duration was approximately 2.6 years. Through the buy-back, the company repurchased a total of 31,261,581 shares, for a total of EUR 641,994,242, equivalent to $750M.

12:04 EDT BMO appoints Kimberley Goode as chief communications, social impact officer - BMO Financial Group announced the appointment of Kimberley Goode as chief communications and social impact officer. She will join the bank in August and report to Cameron Fowler, chief strategy & operations officer. Goode will lead a new team combining the Communications practice areas of Employee Communications, Media Relations, and Government Relations with the Purpose and Community Giving teams, creating a single organization unified in its focus on achieving the bank's strategic priorities and purpose. Most recently, she has held the position of SVP of External Affairs at Blue Shield of California, based in the San Francisco Bay area.

12:00 EDT Owens & Minor falls -4.4% - Owens & Minor is down -4.4%, or -$1.96 to $42.31.

12:00 EDT Onion Global falls -7.0% - Onion Global is down -7.0%, or -30c to $3.96.

12:00 EDT Tuya rises 9.1% - Tuya is up 9.1%, or $1.96 to $23.43.

11:49 EDT Ziosk signs multi-year contract with Red Robin - Ziosk announced the signing of a new multi-year contract with Red Robin Gourmet Burgers. The agreement provides for an upgrade of all the tablets in the field to the most current hardware featuring EMV and NFC contactless payment on demand by the beginning of Q3 2021 and will integrate to the upgraded Red Robin Royalty loyalty platform scheduled to launch later this year.

11:13 EDT CMS Energy plans to end coal use by 2025 - Consumers Energy announced a proposal to stop using coal as a fuel source for electricity by 2025 -15 years faster than currently planned. The plan, which requires regulatory approval, ensures the company will: Be among the first utilities in the nation to go coal-free by 2025; Use 90 percent clean energy resources by 2040; Build nearly 8,000 megawatts of solar energy to power Michigan's homes and businesses by 2040; Stay on the path to achieve net zero carbon emissions, and Save customers about $650 million through 2040. If approved by the Michigan Public Service Commission, the updated plan would speed closure of our three coal-fired units at the Campbell generating complex near Holland. Campbell 1 and 2, collectively capable of producing more than 600 megawatts of electricity, would retire in 2025 - roughly six years sooner than their scheduled design lives. Campbell 3, capable of generating 840 MW, would also retire in 2025 - roughly 15 years sooner than its scheduled design life. The updated proposal also calls for moving up closure of Karn 3 and 4, units that run on natural gas and fuel oil and can generate more than 1,100 MW to meet peak demand, to 2023 - about eight years sooner than their design lives.

10:23 EDT Far Peak Acquisition up 3% after Bloomberg report of Bullish merger talks

10:12 EDT JanOne says prepared to start Phase 2b trials of JAN101 upon FDA approval - JanOne announced that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating Peripheral Artery Disease, or PAD, and is readying the supply for labeling and distribution to clinical sites throughout the U.S. "We are pleased to report that our clinical supply of JAN101 is now ready for near-term release to our expected clinical trial sites in the upcoming Phase 2 clinical trial. We are fully prepared and look forward to FDA approval of our new protocol," said Tony Isaac, President and CEO of JanOne.

10:03 EDT Newmark secures $56M loan for 26-property, 9-state parking facility portfolio - Newmark, on behalf of InterPark Holdings, announces the placement of a $565M, five-year loan secured by a portfolio of 26 cross-collateralized parking facilities located in nine U.S. cities, including Chicago, Philadelphia, St. Louis and Boston. Executive Managing Director Joel Simmons of Newmark's Debt and Structured Finance Group arranged the financing. "InterPark's quality portfolio of parking properties, customer-friendly touchless access and payment mobility systems position the company well for a robust recovery from the effects of the pandemic," said Marshall Peck, CEO of InterPark.

10:01 EDT AIkido Pharma files patent application for use of ketamine to treat Alzheimer's - AIkido Pharma announced that the company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease. "The company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system. This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease," AIkido Pharma said.

10:00 EDT Aluminum Corp. of China rises 7.0% - Aluminum Corp. of China is up 7.0%, or 92c to $14.02.

09:52 EDT Cognizant, Oma Savings Bank terminate contract for core banking project - Oma Savings Bank and Cognizant earlier announced they have mutually agreed to cancel the project and terminate the contract regarding the renewal of the core banking platform commenced in 2019. As part of the agreement Cognizant will pay OmaSp a significant financial compensation, which will have an impact of approximately EUR 22M on OmaSp's profit before taxes for the financial year 2021. CEO Pasi Sydanlammi, OmaSp said, "Negotiations with Cognizant have taken place in good spirits and we concluded that the termination of the cooperation agreement for the core banking project is the best solution for OmaSp. Samlink will continue as an essential IT services provider for OmaSp. The cancellation of the project will have no impact on our customers' banking services and we will continue to develop our digital services in a determined manner."

09:47 EDT Greif falls -4.4% - Greif is down -4.4%, or -$2.74 to $59.04.

09:47 EDT XPeng rises 6.3% - XPeng is up 6.3%, or $2.51 to $42.50.

09:34 EDT CleanSpark set to join Russell 2000 Index, appoints Senior Vice President - CleanSpark announced that it is set to join the Russell 2000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. The company also recently appointed industry veteran Bernardo Schucman as the Senior Vice President of its Atlanta-based Bitcoin mining center. Schucman will oversee its Bitcoin mining and data center operations.

09:31 EDT Amazon announces Prime Day customers spent over $1.9B on small business products - Amazon announced Prime Day 2021 was the biggest two-day period ever for Amazon's third party sellers, nearly all of which are small and medium-sized businesses, growing even more than Amazon's retail business. Prime members in 20 countries shopped more this Prime Day than any previous Prime Day and scored discounts across home, fashion, beauty, and electronics. Members purchased more than 250M items worldwide and saved more than any Prime Day before. Customers spent over $1.9B on more than 70M small business products during the promotional period, more than a 100% year-over-year increase on sales compared to the Prime Day October 2020 promotion.

09:28 EDT Establishment Labs' Motiva implants study showed reduced foreign body response - Yesterday, Establishment Labs "announced results from a landmark study investigating how different breast implant surfaces affect the host immune response. The purpose of the study was to determine the optimal breast implant surface topography that induces the least amount of adverse foreign-body response and understand better how breast implant design impacts biocompatibility. The study... demonstrated that the patented Motiva(R) SmoothSilk surface* significantly reduces the foreign body response compared to implants with high degrees of roughness or completely smooth surfaces that were included in the study. The unique and patented SmoothSilk surface includes a number of elements purposefully designed to improve biocompatibility, including a topography of only 4 microns on average and specific characteristics around skewness and the number, distribution, and size of contact points. The study, led by a team of MIT researchers under the guidance of Professor Robert Langer and lead authors Joshua Doloff and Omid Veiseh, examined the foreign-body responses and capsular fibrosis triggered by miniaturized versions and human-scale commercially available breast implants with different surface topographies (including averages that varied from 0-90 microns) placed in the mammary fat pads of mice and rabbits, respectively, for up to one year. In both the mice and rabbit models, researchers found that tissue exposed to either implants with higher degrees of roughness or completely smooth implants showed increased levels of activity from macrophages - immune cells that normally clear out foreign cells and debris - as well as higher levels of activity in inflammatory T cells, and more scar tissue formation. Surfaces with the SmoothSilk architecture showed a significantly lower level of immune response and the most healthy and biocompatible tissue capsules compared to either completely smooth implants or those with rougher surfaces."

09:24 EDT Globus Maritime announces charter for M/V River Globe - Globus Maritime announced that it has secured a new charter employment for its vessel M/V River Globe. The vessel has been chartered to an unrelated party for a gross daily rate of $29,500. The charter commenced on June 21, 2021 and has a minimum duration of three months and a maximum duration of five months at the charterer's option, which is expected to generate gross revenue of approximately $2.74 million assuming the charter continues for the minimum scheduled period and approximately $4.07 million if the charter continues for the maximum period, in each case assuming no offhire days.

09:21 EDT Intevac announces two additional program awards in Photonics - Intevac announced that it has received two additional Phase 1 development program awards in Photonics. These awards are in addition to the ManTech development award received from the Night Vision and Electronics Sensors Directorate during the first quarter of 2021, which was discussed during the Company's May 3 conference call. The ManTech award continues our work on the current CMOS camera developed in support of IVAS, targeting reduced power and cost, and improved performance. In the new awards announced today, the Enhanced Performance CIS award is aimed at further improving low-light performance for our next-generation CMOS camera, advancing from the current high-starlight operating capability to overcast starlight. The second of the two new awards, the Enhanced Performance EBAPS award, is aimed at significantly improved low-light performance utilizing Intevac's ISIE19 EBAPS technology. This Enhanced Performance EBAPS award is designed to provide ISIE19 low-light performance down to overcast-starlight capability in a greatly reduced form factor required for this application. If selected for Phase 2 development work on all three of these IVAS-supporting programs, funded development revenues for Intevac Photonics would total approximately $23 million over a 36-month period.

09:18 EDT Carnival brands resume cruising in U.S., Caribbean and Europe - Eight cruise line brands from Carnival have announced plans to resume guest cruise operations, with AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&O Cruises (UK) and Seabourn sailing in the United States, the Caribbean and Europe. The brands are resuming operations using a gradual, phased-in approach, with sailings announced on 42 ships to date through the end of fiscal year 2021 (Nov. 30), representing 52% of the company's total capacity across its global fleet of 91 cruise ships. The initial cruises will take place with enhanced health protocols developed in conjunction with government and health authorities, and informed by guidance from the company's public health, epidemiological and policy experts. Additional brand updates on the resumption of guest cruise operations for the remainder of fiscal year 2021 will be announced as further restart plans are finalized.

09:17 EDT Fusion Renewables selects iSun for turnkey development and EPC services - iSun announced that Fusion Renewables has selected the company for turnkey development services and EPC services subject to competitive tendering. The contract represents an initial $1.25M in development financings and construction of 118MW of solar projects across eight sites in North Carolina and South Carolina. The projects were structured by Fusion Renewables, including siting, land control and diligence will be financed and owned by a joint venture between Israel's Modiin Energy and Alon Gas -- both exploration and production companies. The investments mark both companies' first renewable energy investments in the U.S. with an initial target of 118 megawatts peak solar capacity.

09:16 EDT Carnival Cruise Line to grow fleet by two additional ships by 2023 - Carnival Cruise Line announced plans to grow its fleet by two additional ships by 2023, taking the delivery position of an Excel-class ship that had previously been assigned to sister line AIDA Cruises that will arrive in late 2023, as well as taking ownership of Costa Magica from another of its European sister lines, with that ship going through a dry dock, renaming and Carnival-branded conversion and joining the fleet by mid-2022. These two ships are in addition to the new capacity growth represented by Mardi Gras, Carnival's first Excel-class, liquefied natural gas-powered ship which starts sailing from Port Canaveral on July 31 and her sister ship, Carnival Celebration, which will be delivered and sail from Miami starting in late 2022, as part of Carnival's 50th birthday festivities. The addition of these four ships will bring the Carnival fleet to 27 by year-end 2023, and these ships bring many new amenities and features for guests, as well as environmental benefits and enhancements as Carnival continues to exceed and expand targets for emissions efficiencies.

09:16 EDT Southwest announces 2022 executive leadership plans

09:13 EDT Foothills Exploration 'actively looking' at acquisition of oil, gas properties - The Company is actively looking at the acquisition of oil and gas properties with long-lived reserves and upside drilling opportunity. The Company's Wind River Basin program is still undergoing geological delineation to determine the optimal drilling location. A third-party engineering report of the Company's interest in 16,387 acres located in the Wind River Basin, Wyoming, known as the Beaver Creek East Project, indicates Prospective Resources of approximately 21 million barrels of undiscovered oil, with a PV-10 value of $372M. The Company plans to pursue opportunistic drilling opportunities along with an aggressive acquisition program for the remainder of 2021.

09:12 EDT PPG in five-year paint supplier pact with Six Flags, terms undisclosed - PPG ( PPG announced a five-year preferred paint supplier agreement with Six Flags Entertainment (SIX) theme park company and operator of waterparks in North America. Financial details of the agreement were not disclosed.

09:11 EDT Penumbra receives FDA clearance for RED 62 Reperfusion Catheter - Penumbra announced FDA 510 clearance and commercial availability of the RED 62 Reperfusion Catheter, the latest addition to the company's Penumbra System. RED 62 is designed to navigate distal vessel anatomy and deliver aspiration, together with Penumbra Engine, for the removal of blood clots in acute ischemic stroke patients with large vessel occlusions.

09:10 EDT Mirum Pharmaceuticals presents analyses from rare liver disease programs at EASL - Mirum Pharmaceuticals announced the presentation of analyses from its rare liver disease programs during the EASL International Liver Congress. The posters being presented feature an integrated safety analysis of maralixibat in patients with Alagille syndrome, or ALGS, and the unveiling of a multi-national survey of patient reported outcomes from pregnant women with intrahepatic cholestasis of pregnancy, or ICP. The posters are now available on the congress website. Data from more than five years of maralixibat treatment across three Phase 2 clinical studies were analyzed to assess the overall clinical safety of maralixibat in patients with ALGS. The analysis evaluated treatment-emergent adverse events, or TEAEs, and laboratory parameters including reported rates, severity and seriousness, actions taken with maralixibat, time to onset and potential dose-response relationships. A sub-analysis of safety data was also conducted evaluating data from 13-week placebo-controlled studies. Maralixibat was well-tolerated for more than five years. The most common TEAEs were diarrhea and abdominal pain. Mild to moderate gastrointestinal events were observed in the first weeks of treatment, were transient, and lasted less than one week in duration. In placebo-controlled studies, GI events occurred at similar rates between maralixibat and placebo in the background of ALGS. There were no discontinuations of maralixibat due to diarrhea or abdominal pain. No clinically significant trends or patterns in laboratory measures were observed. ALT levels were consistent with natural history comparisons of ALGS.

09:08 EDT Norwegian Cruise Line announces voluntary carbon offset program - As part of its long-term climate action strategy, the Company has launched a voluntary carbon offset program in collaboration with World Kinect Energy Services, the sustainability division of World Fuel Services. The Company has committed to voluntarily offset at least three million MTCO2e through 2023. This is the equivalent of 7,539,593,613 miles driven by an average passenger car or the amount of carbon sequestered in 3,675,533 acres of forests in one year. The Company plans to gradually increase voluntary offset purchases in future years to reach its goal of carbon neutrality based on Scope 1 emissions, which typically account for ~95% of its footprint. This initiative allows the Company to take action immediately and further demonstrates its commitment to addressing climate change even while facing the unprecedented impact on profitability due to the COVID-19 related global voyage suspension. A carbon offset represents one tonne of greenhouse gas emissions that has been avoided or reduced in the atmosphere. Purchasing carbon offsets allows companies to compensate for their residual carbon footprint by supporting projects worldwide that reduce carbon emissions. Through World Kinect, the Company is investing in high-quality, trusted carbon offsets that have been independently verified and meet the highest international standards such as the Gold Standard or the Verified Carbon Standard. The offsets are from a mixed project portfolio that includes renewable energy, forestry, energy efficiency, and waste to energy projects.

09:07 EDT Norwegian Cruise Line creates long-term climate action strategy - Norwegian Cruise Line announced the creation of its long-term climate action strategy and goal to reach carbon neutrality through reducing carbon intensity, identifying and investing in technology including exploring alternative fuels and implementing a voluntary carbon offset program. In addition to ongoing initiatives to reduce its emissions rate, the Company has committed to offset three million metric tons of carbon dioxide equivalent over a three-year period beginning in 2021 to help bridge the gap in its decarbonization efforts until new technology becomes available. As part of the Company's global sustainability program, Sail & Sustain, combating climate change is a material focus and the Company previously signed the Cruise Lines International Association historic commitment to reduce the carbon emissions rate industry-wide by 40% by 2030 from a 2008 baseline. The three focus areas of the Company's long-term climate action strategy include: 1) Reduce Carbon Intensity. The Company continually seeks opportunities to reduce its overall footprint by minimizing fuel consumption and increasing energy efficiency. Ongoing investments in systems and technologies have resulted in a reduction of fuel consumption per capacity day of approximately 17% from 2008 to 2019 for the entire 28-ship fleet. In addition, the Company achieved an estimated approximately 14% reduction in CO2 emissions per capacity day across its fleet between 2015 and 2019. As nine new and more fuel-efficient vessels are introduced to the fleet through 2027, this rate is expected to further decrease. 2) Invest in Technology & Explore Alternative Fuels. The Company has partnered with CLIA and other maritime organizations to propose the establishment of a collaborative shipping research and development fund dedicated to the ultimate goal of eliminating CO2 emissions from international shipping. If approved, funding would come from a contribution per tonne of marine fuel purchased for consumption and is expected to amount to $5 billion over a 10-year period. These funds will be used to finance the development of zero and near-zero GHG fuels and propulsion technologies. As new alternative fuel sources become available at sufficient scale in the future, the Company will evaluate how these can accelerate its long-term carbon reduction strategy. 3) Implement Voluntary Carbon Offset Progam. The Company announced its commitment to purchase carbon credits to offset three million MTCO2e over a three-year period to help bridge the gap in decarbonization efforts until new technology becomes available. Offset purchases are expected to ramp up in future years to reach the goal of carbon neutrality.

09:06 EDT Outset Medical appoints Jean-Olivier Racine as CTO - Outset Medical announced the appointment of Jean-Olivier Racine as Chief Technology Officer. In this new role, Racine will oversee the strategic advancement of Outset's product technology, amplifying the company's data-driven innovation engine to further elevate the patient care experience and drive operating efficiencies for providers.

09:04 EDT Y-mAbs to provide FDA with additional omburtamab data following Type B meeting - Y-mAbs Therapeutics announced that it has recently concluded a Type B meeting with the U.S. Food and Drug Administration regarding omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The company said, "At the Type B meeting with the FDA, available data from external historical control groups and plans for statistical analyses to compare such data with the data from Study 03-133 were discussed. Based on our discussions with the FDA, we believe we now have a clearer path towards the resubmission of the omburtamab BLA to the FDA. Y-mAbs agreed to provide the agency with additional detailed data and the statistical analysis plan and anticipates being able to do so during the third quarter of 2021. Upon receiving the FDA's feedback on these items, we expect to move forward and request a Type B pre-BLA meeting. Pending a positive Type B pre-BLA meeting, we aim to initiate rolling resubmission of the omburtamab BLA by the end of the year."

09:04 EDT Dogness International receives Smart CAM Treaters order for $1M - Dogness announced that a major retailer with close to 600 locations plans to purchase the company's Smart CAM Treaters. Dogness expects the initial order to be valued at approximately $1M.

09:02 EDT Medicenna submits clinical trial application in Australia for study of MDNA11 - Medicenna Therapeutics announced that it has submitted a clinical trial application to a Human Research Ethics Committee in Australia to initiate a Phase 1/2 clinical study of MDNA11, the company's selective, long-acting and novel IL-2 super-agonist. Subject to approval by the HREC and acceptance of the Clinical Trial Notification by Australia's Therapeutics Goods Administration, Medicenna expects to initiate this study in the third quarter of 2021. Additionally, pending successful patient recruitment, the Company intends to provide a preliminary update on safety, pharmacokinetic, pharmacodynamic, and biomarker data by year end. "Submission of this dossier for HREC approval is an important milestone that keeps us on track to execute our broader clinical and corporate strategy," said Fahar Merchant, PhD, President and CEO of Medicenna. "We look forward to the initiation of this trial and reporting results that could support MDNA11's best-in-class potential as a "beta-only IL-2" instead of "not-alpha IL-2" agents currently in the clinic. In addition to MDNA11's first ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study), we are advancing our BiSKITsTM program to identify a new a lead candidate to add to our pipeline while we advance partnering discussions around MDNA55. We are encouraged with recent progress we have made on multiple fronts and are also hopeful that a partnership for MDNA55 will be completed in the coming months. Collectively, our pipeline of opportunities leave us well positioned to achieve a steady cadence of value creating milestones as we work to address the unmet needs of patients." The planned Phase 1/2 ABILITY Study is designed to assess the safety, PK, PD, and anti-tumor activity of various doses of intravenously administered MDNA11 in patients with advanced solid tumors. It includes both, an MDNA11 monotherapy arm as well as a combination arm designed to evaluate MDNA11 with a checkpoint inhibitor. Following its progress in Australia, Medicenna intends to expand the study to the United Kingdom, the United States and Canada.

08:55 EDT Recursion Pharmaceuticals announces multi-year collaboration with Mila - Recursion announced a multi-year collaboration with Mila, the Quebec Artificial Intelligence Institute, to accelerate Recursion's machine learning capabilities. Recursion will open office space within Mila and build a team focused on using machine learning for tech-enabled drug discovery. The Montreal office will collaborate with the company's first major multidisciplinary expansion in Toronto, in addition to its existing headquarters in Salt Lake City, Utah and in vivo biology center in Milpitas, California. Mila's AI ecosystem will allow Recursion access to a network of talented experts, who will work with Recursion toward its goal of radically improving the lives of patients and industrializing drug discovery.

08:51 EDT Eagle Bancorp announces results for modified dutch auction tender offer - Eagle Bancorp Montana announced the preliminary results of its modified "Dutch auction" tender offer to purchase for cash up to $6,000,000 of shares of its common stock at a price per share not less than $24.00 and not greater than $26.25, which expired at 5:00 p.m., New York City time, on June 22, 2021. Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the tender offer, approximately 847,776 shares of common stock were properly tendered and not withdrawn at a price at or below $26.25 per share, including shares that were tendered through notice of guaranteed delivery. In accordance with the terms and conditions of the Tender Offer, and based on the preliminary count by the depositary, the Company expects to acquire approximately 250,000 shares of its common stock at a price of $24.00 per share, for an aggregate cost of approximately $6,000,000, excluding fees and expenses relating to the Tender Offer. These shares represent approximately 3.7 percent of the shares outstanding. The number of shares to be purchased and the price per share are preliminary. They are based on the shares tendered through notice of guaranteed delivery being validly tendered. Such shares are subject to verification by the depositary, and therefore these preliminary results are subject to change. The actual number of shares purchased and the final purchase price will be announced promptly following completion of the verification process. Payment for the shares accepted for purchase, and return of all other shares tendered, if applicable, will occur promptly after completion of the final purchase price computations. The Company also announced that 251,256 shares were sold to the Opportunity Bank of Montana Employee Stock Ownership Plan at a price of $23.88 per share on June 23, 2021. The shares held by the Plan will be used for allocations to employees of the Company over a ten-year period.

08:48 EDT Sachem Capital announces offering of preferred stock - Sachem Capital announced that it has commenced an underwritten public offering of its Series A Cumulative Redeemable Preferred Stock. The terms of the offering, including the number of shares to be offered and sold and the dividend rate are to be determined by negotiations between the Company and the underwriters. The Series A Preferred Stock has a private credit rating of 'BBB' from Egan-Jones Ratings Company, an independent unaffiliated rating agency. In addition, the Company plans to grant the underwriters a 30-day option to purchase additional shares of Series A Preferred Stock on the same terms and conditions to cover overallotments, if any. The Series A Preferred Stock is expected to be listed on the NYSE American and to trade thereon within 30 days of initial issuance.

08:46 EDT Microchip announces availability of MPLAB cloud tools ecosystem - The company said,"Microcontroller design is now easier than ever with the new MPLAB cloud tools ecosystem available today for PIC and AVR devices from Microchip Technology. The free, all-in-one cloud platform combines easy, integrated search and discovery of example code, graphical configuration of projects and code debugging in a collaborative environment. This environment enables enterprise-scale rapid development while simplifying software design for users at all skill levels with an intuitive browser-based interface and cloud connectivity."

08:44 EDT FuelCell announces Betsey Schaefer joins team as new Chief Marketing Officer - FuelCell Energy announced that Betsy Schaefer joined its team as the new Chief Marketing Officer. "Betsy brings experience to FuelCell Energy having built a career at IBM in corporate communications, marketing, and brand management where she most recently led marketing for the Watson AI division," the company said.

08:42 EDT Gilead joint venture receives China NMPA approval for axicabtagene ciloleucel - Kite, a Gilead company, announced that Fosun Kite Biotechnology, a joint venture between Kite and Shanghai Fosun Pharmaceutical has received approval from the China National Medical Products Administration, or NMPA, for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, or LBCL, after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Axicabtagene ciloleucel is the first and only commercially available chimeric antigen receptor T-cell therapy approved in China.

08:42 EDT Amdocs announces new solutions for CES21 suite - Amdocs announced its newest cloud-native suite, CES21, includes embedded and productized analytics capabilities across the entire portfolio, from 5G network functions, to service automation and monetization, and care and commerce. These new intelligent analysis and automation capabilities will enable service providers to better launch, manage and monetize innovative new services in the new network era of 5G and cloud, where the wider range of use cases and telemetry data, and significant new operations complexity, are far beyond human scale to manage.

08:41 EDT Herborium Group reports Q1 sales up 19.7% - Herborium Group announced today that despite the COVID Pandemic and its impact on the economy, The company's performance remains strong and future activities and plans for new products and partnership are in a full swing. First Quarter sales for 2021 grew 19.7% while gross profit increases 15.1% and gross margin grew from 61% to 64%. During this Quarter the company has also retired close to 1/5 of its debt to prepare the Company for upcoming partnership discussions. The First Quarter of 2021 also marked two important events: the introduction of proprietary masks that prevent aerosol supported viral transmission such as Covid-19; expansion of the company's Advisor Board.

08:39 EDT Liminal BioSciences signs share purchase agreement for plasma business sale - Liminal BioSciences announced that Kedrion has exercised its option to acquire the remainder of the company's plasma-derived business under the terms of the Share Purchase Agreement entered into by the company and Kedrion. This acquisition would include the Ryplazim business operated through its subsidiaries, Prometic Bioproduction, the company's plasma-derived therapeutics manufacturing facility and Prometic Biotherapeutics, holder of the biological license application for Ryplazim and associated Rare Pediatric Disease Priority Review Voucher. On June 4, Ryplazim was approved by the FDA as the first treatment of patients with plasminogen deficiency type 1. The Share Purchase Agreement provides for payment of $5M payable upon closing of the sale of the shares of PBP and provides for the right for Liminal BioSciences to receive from PBT an amount equal to 70% of the net proceeds obtained from the sale of a PRV prior the closing of the sale of the shares of PBT. Upon closing of the two transactions, Kedrion would assume all development, manufacturing and commercialization activities and operating costs for Ryplazim.

08:38 EDT Amdocs announces release of Amdocs CES21 - Amdocs announced the release of Amdocs CES21, the latest evolution of its cloud-native, microservices-based, open and modular BSS-OSS integrated suite. The 5G-native CES21 enables service providers to build, deliver and monetize advanced services, leveraging their investments in technologies such as 5G standalone network, multi-access edge computing, software-defined networks, AI and machine learning, and the cloud.

08:38 EDT Chemomab Therapeutics, AGC Biologics expand partnership to manufacture CM-101 - Chemomab Therapeutics and AGC Biologics announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA. Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness. "AGC is a high-quality partner with global manufacturing expertise, and we are pleased to extend our long-standing relationship as we continue to progress in our clinical development," said Adi Mor, Chief Executive Officer. "CM-101 has tremendous potential in treating fibrosis and inflammation, and we are excited to continue to scale up our manufacturing capacity ahead of our Phase 3 registration-enabling trials."

08:36 EDT Entera Bio announce phase 2 BMD data for EB613 - Entera Bio announced the final 6-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone, or PTH, positioned to be the first oral bone building product to treat osteoporosis patients. The Phase 2 clinical trial of EB613 was a 6-month double blind, dose-ranging, placebo-controlled study in 161 postmenopausal female subjects with osteoporosis, or with low bone mineral density. This study was conducted at four leading medical centers in Israel to evaluate the safety and efficacy of varying doses of EB613. "The most important BMD endpoint - change in lumbar spine BMD after 6 months - was met," the company said. There were statistically significant dose-related trends in the increases in LS BMD as well as femoral neck and total hip BMD, with the largest increases observed in subjects treated with EB613 2.5 mg. Dose dependent increases in biochemical markers of bone formation were previously reported. A significant increase in lumbar spine BMD was observed in the 1.5 mg group, the non-titrated 2.5 mg group and the titrated 2.5 mg group. An increase in LS BMD is the primary endpoint for the 505b2 pathway as was described by the FDA in Entera's pre-IND meeting. At present it is believed that the single Phase 3 Pivotal study necessary under the 505b2 pathway would require a 12-month head-to-head study against Forteo, designed to achieve non inferiority for increase in BMD of the lumbar spine. Increases in LS BMD versus placebo observed at 6 months in previous Forteo studies conducted with similar patient populations, were in the 3.9% range. In the current study LS BMD increased 3.78% in the group treated with 2.5 mg for the full 6 months. When this group was combined with the titrated 2.5 mg group LS spine BMD increased, 2.73%. Furthermore, EB613 had a significant impact on both femoral neck and total hip BMD at 6 months. In this dose-ranging study, various doses of EB613 were tested for their effect on markers of bone metabolism after 3 months and BMD of the lumbar spine, femoral neck, and total hip after 6 months. As previously reported, the trial's primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment as compared to placebo. P1NP is a biomarker that indicates the rate of new bone formation. Secondary endpoints in the trial included the effect of treatment on several additional serum bone biomarkers at 3 months including, Osteocalcin and CTX. The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMD and a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment, as reflected in the 6-month BMD results. The study medication, EB613, was generally well tolerated throughout the 6 months of treatment. There were no adverse events that were severe in intensity in any treatment group and no serious drug-related adverse events. However, subjects randomized to the 2.5 mg dose of EB613 presented a higher rate of adverse events, which are in line with AEs known to be associated with daily injections of PTH, such as nausea, headaches, and dizziness.

08:35 EDT Luokung Technology subsidiary's HD map standards approved in China - Luokung Technology announced that the Intelligent and Connected Vehicles-Highly Automated Driving Map-Acquisition Element Model and Exchange Format standard, sponsored by Luokung's wholly-owned subsidiary eMapgo Technologies, a provider of navigation and electronic map services in China, has passed the project approval and review process by the China Society of Automotive Engineering Standards and was approved for official release. This is the first published industry standard for the Highly Automated Driving Map production industry in China. It sets the foundation for future intelligent and connected vehicles Highly Automated Driving Map exchange formats and for mapping- and positioning-related standard systems for a cohesive and intelligent network. The standard, whose development was led by EMG over the course of 16 months, was jointly completed by more than 20 companies.

08:33 EDT XBiotech announces first patient enrolled in clinical trial evaluating XB2001 - XBiotech has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer. XBiotech's novel anti-cancer agent, XB2001, is being assessed in combination with ONIVYDE + 5-FU/LV chemotherapy regimens. Safety and tolerability of the regimen, as well as progression-free survival, overall survival and time-to-treatment-failure will be assessed in the study. The study is also investigating a novel clinical endpoint that XBiotech calls the "clinical benefit response", which involves radiological assessment of muscle mass and patient reported measures of pain, fatigue and appetite. In earlier clinical studies in advanced cancer patients, XBiotech discovered that subjects with preserved muscle mass and stabilization or improvement of these symptoms, had dramatically improved overall survival. The Company previously validated this endpoint in a phase III study in colorectal cancer patients and will explore this endpoint now with its new drug in pancreatic cancer. The current study will commence with a Phase 1 portion to establish safety, tolerability and dosing of XB2001 in combination with ONIVYDE+5-FU/LV. The Phase I portion will serve to establish a recommended Phase 2 dose, which will involve enrollment of 60 patients randomized to receive either placebo+ONIVYDE+5-FU/LV or XB2001+ONIVYDE+5-FU/LV for up to 12 cycles.

08:32 EDT Jounce Therapeutics provides update on INNATE study at 2021 R&D Day - Jounce Therapeutics announced a comprehensive update on its discovery and clinical-stage pipeline at its 2021 virtual R&D Day. Presentations will highlight Jounce's productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064. In addition to presentations from Jounce management and scientific team members, key opinion leader and one of Jounce's scientific founders, Robert Schreiber, Ph.D., Distinguished Professor of Pathology and Immunology at The Washington University School of Medicine, will discuss the scientific rationale for targeting myeloid cells and the therapeutic potential of re-programming macrophages through inhibition of LILRB2. "Jounce is at an exciting time in its life cycle and I am incredibly pleased to have the opportunity to share the latest developments on our discovery and clinical stage pipelines, while also sharing a look into our productive and validated Translational Science Platform. More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064. Thanks to a high level of investigator engagement and dedicated efforts from our team, the timing of expansion cohort initiations is now expected in the third quarter of this year," said Richard Murray, Ph.D., Chief Executive Officer and President of Jounce Therapeutics. "Our pipeline has been built to bring forward new biomarker-enabled immunotherapies to address the evolving unmet needs of cancer patients, whose tumors may be sensitive or resistant to today's approved immunotherapies." R&D Day Presentation Highlights Include: Utilization of Jounce's Translational Science Platform to investigate the tumor microenvironment and identify cell type-specific targets with unique biology; Overview of differentiated biomarker approach from discovery through development; Introduction of new discovery programs focused on additional LILRB family members, including LILRB1 and LILRB4; Update on monotherapy dose escalation and receptor occupancy from the INNATE clinical trial of JTX-8064; Announcement of timing of INNATE clinical trial monotherapy and pimivalimab combination expansion cohort initiation, expected in the third quarter of 2021; Update on continued progress on Jounce's first biomarker patient selection study, SELECT.

08:31 EDT Esports Technologies files patent for live streaming wagering technology - Esports Technologies has filed a comprehensive provisional patent application for its technology that enhances the betting experience for sports and esports live streaming events. The provisional patent filing covers a proprietary technology that integrates sports and esports wagering across many of the world's most popular live streaming platforms, including Twitch, YouTube, Amazon TV & Gaming, Facebook Gaming, and Hulu among others. All of the in-browser technology will be powered by Esports Technologies' real-time data feed.

08:29 EDT CN to invest C$460M in British Columbia in 2021 - CN announces plans to invest approximately C$460 million in British Columbia in 2021 as part of CN's C$3 billion capital investment plan across its network. In British Columbia, CN's investment will focus on technology, capacity, and infrastructure maintenance to enhance safety and the fluidity of its network.

08:26 EDT James River Group's Chief Operating Officer Robert Myron to retire - James River Group announced the retirement of Robert Myron, President and Chief Operating Officer, after more than 11 years with the organization. Myron will retire effective July 31, 2021 for health reasons related to lingering effects of Lyme Disease. The company and Myron expect to maintain a consulting relationship through December 31, 2021.

08:24 EDT E-Home Household Service's variable interest entity acquires Jiajiale - E-Home Household Service's affiliated variable interest entity, Fuzhou Fumao Health Technology, entered into an equity transfer agreement with Fuzhou Gulou Jiajiale Family Service, a household services company in Fuzhou, China, pursuant to which Fumao will acquire 100% of equity interests of Jiajiale in cash. Founded in 2004, Jiajiale is a care provider in Fuzhou, China, mainly providing nanny, maternity matron, housekeeping and other household services.

08:23 EDT Teva says MHLW approves fremanezumab injection in Japan for migraine - Teva Pharmaceutical announced the Ministry of Health, Labour and Welfare MHLW has approved the use of AJOVY, fremanezumab, injection for the preventive treatment of migraine in adults in Japan. "In Japan, the annual prevalence of migraine is 8.4% of adults1 and now, together with our partner, Teva is able to offer people living with migraine in Japan this biopharmaceutical treatment with flexible dosing options to help manage this unpredictable disease," said Sven Dethlefs, PhD, Executive Vice President, International Markets Commercial Region and Global Marketing and Portfolio at Teva. "Driven by our global mission to improve patients' lives, we are pleased to offer this new treatment option to people living with migraine in Japan."

08:21 EDT Arcutis appoints Greg Sukay as VP, manufacturing and process technologies - Arcutis Biotherapeutics (ARQT) announced that Greg Sukay has joined the company as Vice President, Manufacturing and Process Technologies. Mr. Sukay will oversee Arcutis' external manufacturing and process development for its pipeline of medical dermatology programs. Prior to joining Arcutis, Mr. Sukay spent more than 22 years at Amgen (AMGN), where he most recently served as Executive Director of Amgen Contract Manufacturing.

08:20 EDT Aemetis negotiating supply of 1.6M MT per year of CO2 for carbon sequestration - Aemetis announced that it has opened negotiations for the supply of 1.6M metric tonnes, or MT, per year of CO2 for Carbon Capture and Sequestration to be located at or near the two Aemetis renewable fuels plant sites in Central California near Modesto. It is anticipated that the capacity of each injection well site will be approximately one million metric tonnes per year, for a combined total of two million MT of CO2 sequestration per year. Recently, the Aemetis Carbon Capture subsidiary was established to build carbon sequestration projects to generate LCFS and IRS 45Q credits by injecting CO2 into wells which are monitored for emissions to ensure the long-term sequestration of carbon underground. California's Central Valley is well established as a major region for large-scale natural gas production and CO2 injection projects due to the subsurface geologic formation that retains gases. The planned 52 dairies in the Aemetis Biogas project are expected to produce approximately 50,000 metric tonnes of CO2 each year. The renewable jet/diesel plant under development is expected to produce more than 200,000 metric tonnes per year of CO2. The remaining 1.6M metric tonnes of annual CO2 injection capacity are expected to be filled by compressed CO2 delivered via truck or rail to the two Aemetis CCS sites from renewable diesel plants and refineries that supply fuels to the California market. The Aemetis Carbon Zero project, the Aemetis Biogas renewable natural gas project, and energy efficiency upgrades to the Aemetis Keyes plant include $57M of grant funding and other support from the USDA, the US Forest Service, the California Energy Commission, the California Department of Food and Agriculture, CAEFTA, and PG&E's energy efficiency program.

08:19 EDT Amdocs announces business momentum of eSIM platform - Amdocs announced the business momentum of its cloud-based eSIM platform, as well as new capabilities for service providers across the globe. Worldwide, Amdocs has been awarded 12 new projects across 10 countries in recent months, including an eSIM for enterprise solution for a European service provider. Amdocs also delivered a successful go-live for a significant Asia-Pacific service provider, which launched eSIM for Apple devices, such as MacBook, iPhones and Apple Watches

08:17 EDT AgroFresh Solutions announces global licensing agreement with Know Hub Chile - AgroFresh Solutions announced an exclusive global licensing agreement with Know Hub Chile to test and potentially commercialize patent pending technology for superficial scald control in apples and pears. The agreement continues AgroFresh's commitment to preserving produce freshness and potentially offers a new natural solution to help extend produce shelf life and reduce food loss and waste. The Know Hub Chile technology, first developed by and licensed from the University of Talca in Chile, is based on a natural lipid found in plants. Existing solutions to prevent scald often include Ethoxyquin or Diphenylamine, antioxidant solutions that have residue levels and are banned from use in the European Union. The new technology may provide a naturally derived solution to manage scald that could be available for drench, dip and fogging applications. AgroFresh anticipates that customer trials will begin during the 2021-2022 Northern Hemisphere pome fruit season.

08:15 EDT Washtenaw Community College enrolls in DTE Energy's MIGreenPower Program - DTE Energy and Washtenaw Community College announced the college's enrollment in DTE Energy's MIGreenPower voluntary renewable energy program. MIGreenPower provides DTE customers with an easy, low-cost option to access more clean energy without installing onsite generation. The first community college to enroll in the program, WCC has committed to an escalating enrollment that will begin in 2023 and increase annually with the college sourcing 100% of its electric power needs through clean energy by 2029.

08:15 EDT Assembly Biosciences presents data from HBV core inhibitor programs - Assembly Biosciences announced data from its three clinical-stage core inhibitor programs, vebicorvir, ABI-H2158, and ABI-H3733, in an oral presentation and two poster presentations during the International Liver Congress 2021, the Annual Meeting of the European Association for the Study of the Liver, taking place virtually June 23-26, 2021. In an oral presentation, William Delaney, Chief Scientific Officer, describes data evaluating human plasma and estimated liver concentrations of VBR, 2158, and 3733 in relation to their respective protein-adjusted EC50 values in primary human hepatocytes. The intent of the analysis was to assess antiviral activity and prevention of formation of new cccDNA of each of the three candidates. Plasma Cmin values for VBR, 2158, and 3733 are significantly above protein-adjusted EC50 values for antiviral activity, and plasma Cmin values of 2158 and 3733 are significantly above protein-adjusted EC50 values for cccDNA prevention. Concentrations for VBR, 2158, and 3733 are predicted to be enhanced in the liver by 18-fold, 5-fold, and 6-fold, respectively. VBR is featured in two poster presentations during EASL, describing the efficacy, safety and resistance profile of virologically-suppressed patients with chronic HBV infection enrolled in the Phase 2 Studies 201 and Study 211 of VBR in combination with NrtI who discontinued treatment. Edward Gane reported that combination therapy with VBR and NrtI for an extended period was well-tolerated and resulted in deep virologic suppression, but did not result in sustained virologic response in any patient who met prospective treatment stopping criteria. Post hoc analyses suggest HBcrAg level may be an important component when establishing stopping criteria for future trials. Patients were categorized as having lower or higher off-treatment viral load to enable a univariate logistic regression analysis to evaluate predictive factors. For HBeAg negative patients, entecavir use and HBcrAgless than1.5 kU/mL at end of therapy were significant predictors of off-treatment lower viral load. For HBeAg positive patients, age less than 45 years was a significant predictor. Discontinuation of VBR+NrtI was well tolerated with limited adverse events and ALT elevations post-NrtI restart. Man-Fung Yuen described a post hoc analysis to investigate whether treatment-emergent core inhibitor substitutions were observed following discontinuation of VBR and NrtI. Sanger sequencing of HBV core and pol/RT was performed on HBV RNA for baseline samples and on HBV DNA for the first two consecutive off-treatment visits with HBV DNA greater than 20 IU/mL. In vitro phenotyping assays were conducted for all novel substitutions observed in the core inhibitor binding pocket. The majority of patients had no core inhibitor substitutions and those that were observed had minimal impact on the in vitro antiviral activity of VBR. There was no emergence or enrichment of core substitutions observed in any patient. For patients who restarted NrtI, the presence of core inhibitor substitutions did not impact HBV DNA resuppression, nor did it impact the level of viremia off treatment.

08:14 EDT Gritstone appoints Economides as CFO, announces Yelensky stepping down as CTO - Gritstone bio (GRTS) announced the appointment of Celia Economides as executive vice president and chief financial officer. Economides was most recently senior vice president, Strategy and External Affairs at Kezar Life Sciences (KZR), a public company targeting immune-mediated diseases and cancer. Separately, the company announced that Roman Yelensky, Ph.D., executive vice president and chief technology officer, will be stepping down to co-found and lead a new startup in the cancer diagnostics space, working alongside a major healthcare investor.

08:13 EDT AerSale to join Russell 2000 Index - AerSale is set to join the Russell 2000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021. Index membership means automatic inclusion in the appropriate growth and value style indexes also and remains in place for one year.

08:12 EDT Amdocs announces Policy, Charging Control as-a-service offering - Amdocs announced that its Policy and Charging Control offering can now be delivered in the cloud, managed as a service, as well as on-premise. Amdocs Charging software serves more than 1 billion subscribers and its Policy software serves more than 500 million subscribers at leading service providers across the globe, including a number of deployments in various public clouds. This new evolution facilitates service providers in embracing and establishing commercial value on the multiple new technical currencies that are emerging within 5G networks.

08:11 EDT H2O Innovation signs $5M contract from Town of Warren, Rhode Island - H2O Innovation announced it has recently been awarded the Operations and Maintenance contract for the Town of Warren, Rhode Island with a total value of $5.0 M, bringing the Corporation's O&M sales backlog to $71.3 M. This award follows a competitive RFP process. The new contract includes the supply of operation and maintenance services for a 2 MGD wastewater treatment facility and pumping stations for a 5-year period and adds 6 new employees to the O&M team. The contract, which officially begins on July 1st, 2021, is remarkable because in 1980 Warren became only the second city in the United States to privatize their operations.

08:10 EDT PTC Therapeutics' Evrysdi approved in Japan for spinal muscular atrophy - PTC Therapeutics' (PTCT) Evrysdi was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy, or SMA. The approval has been granted based on data from two pivotal studies evaluating Evrysdi in infants and adults living with type 1, 2 or 3 SMA. The first commercial sale will trigger a $10M milestone payment to PTC from Roche (RHHBY) under its License and Collaboration agreement. Evrysdi has been approved for the treatment of patients with SMA, aged 2 months and older by the FDA and the EMA. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi is marketed in the U.S. by Genentech, a member of the Roche Group.

08:10 EDT Zebra Technologies receives STIG validation from DISA - Zebra Technologies announced that it has received STIG validation from the Defense Information Systems Agency, or DISA. This validation allows U.S. military agencies to purchase and deploy 28 different Zebra Android 10-based mobile devices on U.S. Department of Defense, or DoD, network systems, all of which are now listed on the Department of Defense Information Network's approved products list. STIG validation is a security review and configuration standard that helps ensure IT products and military agencies are complying with DoD security policies.

08:10 EDT John Wiley boosts annual dividend to $1.38 per share - John Wiley and Sons announced that its Board of Directors has declared a quarterly cash dividend of 34.50c per share on its Class A and Class B Common Stock, payable on July 21 to shareholders of record on July 6.The quarterly dividend is equivalent to an annual dividend of $1.38 per share, an increase from $1.37 per share in Fiscal 2021. It was Wiley's 28th consecutive annual increase. In Fiscal 2021, Wiley grew Free Cash Flow by 48% to $257M distributing $77M for dividends and $16M for share repurchases. The Company ended the year with a Net Debt-to-EBITDA ratio of 1.7.

08:08 EDT Home Depot launches online rental reservations - The Home Depot is enhancing the customer experience at its 1,300 rental locations with the launch of new "Rent Online, Pick-up In Store" technology. From demolition tools like breakers and concrete saws to landscaping tools like tillers and sod cutters to trailers and moving vehicles, customers can now reserve and rent equipment online up to 30 days in advance. After piloting online reservations in the Atlanta, Charlotte and Houston markets, The Home Depot has made the system available to rental customers across North America. The Home Depot also has opened eight new Rental Centers since January, further expanding its leadership as the largest equipment rental network in the U.S.

08:07 EDT Biogen says engaging with public, private payers to support access to Aduhelm - Biogen (BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co. (EASLY), issued a statement to for the Alzheimer's disease community, stating in part: "On June 7, 2021, Aduhelm 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration. We are committed to responding to questions from the Alzheimer's disease community and providing more details about our plans... We have determined the launch price of Aduhelm based on our belief in the impact of treatment as well as the size of the appropriate patient population based on the entry criteria of our clinical trials. In the event that our fundamental assumptions on population size and rate of adoption are significantly different than expected, we stand ready to work with public and private payers to address pricing in order to achieve both patient access and support budget sustainability. We have been engaging directly with public and private payers and health systems to ensure coverage policies support access for appropriate patients... We are committed to engaging with CMS on innovative price and access agreements, including but not limited to, volume-based agreements that would help support continued sustainability of Medicare budgets. As part of our commitment to budget sustainability, Biogen will not be increasing the price of Aduhelm in the first four years following launch. We are committed to providing access to Aduhelm for patients across a spectrum of financial situations. We operate within the existing health insurance and legal system that limits the company's ability to subsidize out of pocket expenses for Medicare patients while generally allowing such assistance for commercially insured patients." Reference Link

08:06 EDT Titan Pharmaceuticals' TP-2021 shows efficacy in reduction of chronic pruritus - Titan Pharmaceuticals (TTNP) announced that the in vivo study of its human kappa-opioid receptor agonist TP-2021 ProNeura-based implant in an established 5'-guanidinonaltrindole itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus, or itch. Subcutaneously injected TP-2021 was compared to difelikefalin - Korsuva, which is in late-stage development by Cara Therapeutics (CARA) - , across multiple indications, including intravenous treatment of hemodialysis patients with chronic pruritus, and was observed to be equally potent in reducing scratching and grooming behaviors in this established animal itch model. Based on the positive data with subcutaneous injection of TP-2021 and the selective binding exhibited by TP-2021 at the kappa opioid receptor, Titan tested ProNeura-based TP-2021 implants in an initial study. Results from these studies demonstrated that the experimental TP-2021 implants provided sustained itch suppression for a period of 14 days post-implantation. Mouse implant provided sustained plasma concentrations of TP-2021 that were well above the levels observed to provide therapeutic anti-pruritus activity after acute administration.

08:05 EDT Farmers National Banc to acquire Cortland Bancorp in $124M deal - Farmers National Banc Corp. (FMNB), the holding company for The Farmers National Bank of Canfield, and Cortland Bancorp Inc. (CLDB), the holding company for The Cortland Savings and Banking Company, jointly announced they have entered into an agreement and plan of merger. Pursuant to the Agreement, each shareholder of Cortland may elect to receive either $28.00 per share in cash or 1.75 shares of Farmers' common stock, subject to an overall limitation of 75% of the shares being exchanged for Farmers shares and 25% for cash. Based on Farmers' closing share price of $16.87 on June 22, 2021, the transaction is valued at approximately $124.0 million or $29.14 per share. The merger is expected to qualify as a tax-free reorganization for those shareholders electing to receive Farmers' shares. The transaction is subject to receipt of Cortland shareholder approval and customary regulatory approvals. The transaction is intended to close in the fourth quarter of 2021. At the close of the transaction, James M. Gasior, Cortland's President and CEO will join Farmers executive team as Senior Executive Vice President and Corporate Development Officer. Timothy Carney, Cortland's Executive Vice President and COO will join Farmers as Senior Executive Vice President and Chief Banking Officer. Furthermore, Farmers intends to name two directors from Cortland's Board to join its Board of Directors. Upon consummation of the transaction, The Cortland Savings and Banking Company will be merged with and into Farmers National Bank and Cortland's branches will become branches of Farmers National Bank. Upon closing, Farmers estimates it will have approximately $4.1 billion in assets and 48 locations throughout Ohio and western Pennsylvania. As of March 31, 2021, Cortland had total assets of $791.7 million, which included gross loans of $518.6 million, deposits of $680.3 million and equity of $81.1 million.

08:04 EDT Box appoints Diego Dugatkin as Chief Product Officer - Box announced the appointment of Diego Dugatkin as Senior Vice President and Chief Product Officer. Most recently, Dugatkin was Vice President of Product Management for Adobe Document Cloud, leading strategy and execution for the Adobe Acrobat family of products across mobile, desktop and web, as well as Adobe Sign, with a focus on both enterprise and SMB segments. Dugatkin was also responsible for product management of the vast ecosystem of partnerships and integrations of Adobe's Document Cloud with major products and brands, such as Microsoft, Salesforce, Workday, and many others.

08:04 EDT KnowBe4 names Michael Williams as new Chief Marketing Officer - KnowBe4 announced it has hired a new chief marketing officer, Michael Williams. In this role, Williams will be responsible for developing KnowBe4's global marketing and PR strategy. Williams has nearly 30 years of business and tech experience, with more than 20 of those years specifically in marketing, where he has specialized in the areas of demand generation and brand development. Previously, Williams was chief marketing officer for D2iQ where he led a successful re-branding effort, including a new corporate identity, company strategy, message and product suite.

08:03 EDT PAE awarded $12.8M contract by U.S. AID for Bangladesh agricultural development - PAE was awarded a five-year, $12.8M contract by the United States Agency for International Development, AID, to support the Agency's Feed the Future Bangladesh Agricultural Infrastructure Development Activity. PAE will build the capacity of the Government of Bangladesh's Local Government Engineering Department to modernize infrastructure in priority rural farming communities. The Activity will consist of improvements to roads, irrigation and drainage systems, as well as market and collection centers, and cold storage facilities as a means of increasing access to markets, strengthening agricultural production, and improving farmers' livelihoods. "PAE will strengthen the LGED's capacity to strategically plan, construct and maintain rural infrastructure in the Feed the Future Zone of Influence and the USAID/Bangladesh Zone of Resilience target geographic areas. To minimize post-harvest losses, the work will improve roads, support irrigation operations and maintenance, and develop best practices for lasting, sustainable change," the company said.

07:59 EDT Greif raises price for all uncoated recycled paperboard grades by $50 per ton - Greif is implementing a $50 per ton price increase for all grades of uncoated recycled paperboard - URB - effective with new orders and shipments on and after July 26. This price increase is in response to ongoing cost pressures in production and transportation and continued robust demand across the Greif paperboard network.

07:55 EDT Cortland Bancorp Inc trading halted, news pending

07:48 EDT VivoPower's EV conversion kits to electrify Toyota Australia's Land Cruiser - VivoPower (VVPR) announced an exclusive manufacturing collaboration with Toyota (TM). Toyota Australia intends to integrate VivoPower's conversion kits to electrify its Land Cruiser vehicles during the build process, turning chassis originally destined to be diesels into emission-friendly EVs with VivoPower batteries and electric motors. The deal follows two years of collaboration and field trials in the environment of the Australian mining sector. Whilst the Letter of Intent is not the final contract, it is binding and the end agreement is expected to lock out VivoPower competitors from working with Toyota Australia to electrify Land Cruisers. Since last year, VivoPower has signed three agreements, spanning mining markets including Australia, Canada and the Nordics. Together the deals envisage VivoPower delivering at least 4,475 kits to those regions in the next five and a half year with a total revenue of EUR268.5M. Toyota sells c 400,000 Land Cruisers a year worldwide, with over 25,000 sold in Australia in 2020.

07:37 EDT Lizhi podcast launches on Tencent WeScenario - LIZHI INC. (LIZI) announced that its vertical podcast platform LIZHI Podcast has officially launched on the Tencent WeScenario (TCEHY) in-car platform.

07:36 EDT Theratechnologies appoints Frank Holler to board of directors - Theratechnologies announced the appointment of Frank Holler as a new independent member to its board of directors. Frank Holler is currently President & CEO of Ponderosa Capital.

07:35 EDT Conformis announces exclusive distribution agreement in China - Conformis announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group Limited. Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis' patient-specific iTotal CR & PS total knee replacement systems, iTotal CR & PS patella devices, and iUni and iDuo partial knee replacement systems. Other products, such as Conformis' recently approved Identity Imprint knee system and its hip portfolio of products, may be added in the future. XR Medical's sales team will provide sales and support exclusively to facilities in Hainan's Boao Lecheng International Medical Tourism Pilot Zone on behalf of Conformis. The region is a major center of medical tourism for dozens of countries. "This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis' international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China," said Mark Augusti, President and CEO of Conformis. "What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China."

07:33 EDT ReTo Eco-Solutions announces new tailings treatment project in China - ReTo Eco-Solutions announced a new iron tailings project in the Hainan Province with a 3M-ton treatment capacity, which is expected to yield approximately $43.7M annual sales after reaching production. ReTo will design, build and manage a facility in the Hainan Province and this latest project will be responsible for the largest volume of iron tailings in Hainan. ReTo was selected by the local government. The company expects to generate $20.4M of gross profit from the Project. The remaining material from the company's production can also be used as an aggregate to produce building materials. Iron ore tailings volume has accelerated in China in recent years due to its rapid economical growth, and expansion in iron and steel industries.

07:33 EDT Cerecor divests non-core neurology pipeline assets to Alto Neuroscience, ES - Cerecor announces that it has divested its non-core neurology pipeline assets to Alto Neuroscience and ES Therapeutics, respectively. The company previously disclosed its intentions to explore strategic alternatives for these neurology pipeline assets, which are non-core to the company's business, and focus on developing innovative therapies in areas of high unmet need within the fields of immunology, immuno-oncology, and rare genetic disorders. As part of the divestitures, Cerecor will receive undisclosed initial payments and is eligible to receive additional payments upon achievement of specified development, regulatory and sales-based milestones. Cerecor is also entitled to royalty payments based on net sales of CERC-301.

07:32 EDT Heat Biologics to expand R&D facilities in Morrisville, North Carolina - Heat Biologics announced the expansion of its research and development facilities in Morrisville, North Carolina. The expansion will support the addition of enhanced research and development capabilities including in-house synthesis of antibodies and other drugs/reagents as well as an expanded vivarium for onsite pre-clinical studies. Jeff Wolf, CEO of Heat Biologics, stated, "We are delighted to announce plans to double the size of the current facilities to support and accelerate activities around our oncology and non-oncology programs. By bringing more of our development and pre-clinical activities in-house, we expect to accelerate R&D timelines and generate cost savings on research and development that would have otherwise been achieved through use of third-party service providers. We look forward to leveraging these new facilities as we accelerate our discovery and development efforts."

07:12 EDT Xebec Adsorption commissions on-site hydrogen generation system for TAYRAS - Xebec Adsorption announce that its wholly owned subsidiary HyGear, has successfully commissioned an on-site hydrogen generation system for TAYRAS' used lubricant oil re-refinery in Turkey. Approximately 560 kg of hydrogen per day will be delivered under 125 bar by the fully automated system under a 15-year Gas-as-a-Service contract. TAYRAS' facility is the first of its kind in the country and will be key to developing Turkey's circular economy and reducing emissions from API Group II base lubricating oils. The capacity of TAYRAS' plant is 60,000 tons of used lubricating oil per year which is expected to produce approximately 45,000 tons of Group II base oil. The hydrogen produced by HyGear's system will be used to hydro-treat the used oils and remove sulphur, chlorine, nitrogen, phosphorous, silica and saturation of aromatics employing special catalysts.

07:10 EDT Calibre Mining publishes inaugural 2020 sustainability report - Calibre Mining announced the Company has published its inaugural 2020 Sustainability Report. The Report outlines the Company's achievements and progress during 2020 and provides guidance for the Company's Environmental, Social and Corporate Governance initiatives for 2021. 2020 Highlights: People: Our workplace: 2,754 employees and contractors, of which 98% are Nicaraguan nationals with 65% from the local communities where we operateHeld 748 transparent and open community engagement meetings; Conducted four public consultations, all resulting in project approval. Socio-Economic Benefits: Distributed $198.4M total economic value to our host country of Nicaragua through wages and benefits to employees, contracts to suppliers, taxes, and community investments. Health & Safety: Developed a "ONE CALIBRE" Organizational Health & Safety Culture Program; Executed a self-imposed ten-week COVID-19 response shutdown in Q2/2020; Implemented new rigorous health and safety procedures and protocols; Reduced Lost Time Injury Frequency Rate by 12% compared to full year 2019. Environment: Zero significant environmental incidents, including no notices of violations, fines or sanctions; Established multi-stakeholder partnership in Rancho Grande for water conservation Governance; Joined the World Gold Council and working to comply with all Responsible Gold Mining Principles; Advancing alignment with the UN Sustainable Development Goals; Integrating and adhering to updated governance and social responsibility policies and procedures

07:08 EDT Clovis announces LuMIERE study of FAP-2286 open for enrollment - Clovis announced that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein is now open at the O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham.

07:07 EDT Foxconn, Gogoro enter MOU for technology and manufacturing partnership - Foxconn and Gogoro announced they had signed a memorandum of understanding, or MOU, to form a strategic technology and manufacturing partnership. Together, the companies will accelerate Gogoro's expansion by utilizing Foxconn's manufacturing capabilities to introduce new levels of manufacturing capabilities and scale for Gogoro battery swapping technologies and Smartscooters. The announcement follows Gogoro's recent market announcements in India and China and growing interest for its battery swapping ecosystem around the world. Foxconn and Gogoro will begin collaborating on multiple projects including smart batteries, vehicle engineering and manufacturing. By integrating Foxconn's strong manufacturing, global capabilities and top quality, Gogoro will focus on its own product design, technology development, marketing and branding, expanded distribution and customer service channels.

07:05 EDT Olink announces Olink Explore 3072 platform - Olink Holding announced that it is taking orders for Olink Explore 3072, providing customers with access to its expanded library of ~3000 carefully curated and validated assays. Olink Explore 3072 significantly expands the company's Explore protein biomarker discovery offering, featuring its proprietary Proximity Extension Assay high-multiplex immunoassay technology combined with next-generation sequencing readout on the Illumina NovaSeq and Illumina NextSeq platforms. With this expansion, Olink will double the number of available protein biomarker targets, covering all major biological pathways, and increasing the dynamic range while maintaining unparalleled sensitivity, specificity and precision. By using Olink Explore 3072, customers can experience a throughput of just over 4600 samples per week per system, with almost 3000 proteins measured for each sample. The company will begin taking orders for kits and studies based on the expanded library beginning today, with deliveries expected to begin in the fourth quarter, 2021.

07:03 EDT Winnebago CEO says 'pleased with' strength of business - CEO Michael Happe continued, "As we enter the final quarter of Fiscal 2021, we are pleased with the strength of our business and the unique appeal of our leading brands. We remain focused on working with our suppliers to sustain strong levels of production and with our dealer network to replenish their inventories in the face of record backlog. We are also continuing to invest in our business to ensure we are best positioned to meet the persistent, elevated demand we anticipate in quarters to come, driven by the secular and ongoing growth in outdoor lifestyle products and a positive change in consumer preferences for leisure and family activities. I am also incredibly proud of Winnebago Industries' unwavering commitment to stewardship of the environment and the communities in which we live and operate. During the quarter, we announced our participation in the United Nations Global Compact - a corporate sustainability initiative designed to advance universal principles on human rights, labor, environment and anti-corruption - and initiated a partnership with Habitat for Humanity, a global housing nonprofit, to support its community-based neighborhood revitalization efforts. These organizations' missions are clearly aligned with Winnebago Industries' values and enable more communities to safely and equitably enjoy the outdoors where they live, work and play."

07:03 EDT Editas Medicine announce enrollment of first cohort in trial of EDIT-101 - Editas Medicine announced that centers are now enrolling the first of two planned pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101 following the Independent Data Monitoring Committee endorsement to proceed. The IDMC endorsement is based on an analysis of safety data from the adult low-dose and adult mid-dose cohorts. The company also announced the completion of dosing of the adult mid-dose cohort. Both the pediatric mid-dose cohort and the adult high-dose cohort will run concurrently. For both cohorts, first dosing is expected this summer and completion is expected in the first half of 2022. EDIT-101 is under development for the treatment of Leber congenital amaurosis 10. The company plans to present initial clinical data from the BRILLIANCE clinical trial at an upcoming medical meeting and is currently submitting an abstract to the International Symposium on Retinal Degeneration planned for September in Nashville.

06:57 EDT Becton Dickinson receives FDA clearance for PeritX Peritoneal Catheter System - Becton Dickinson announced it has received 510(k) clearance from the FDA for the PeritX Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites. Ascites is a debilitating condition that causes the build-up of fluid in the abdomen.

06:48 EDT Wex signs new fleet card agreement with state of California - Wex has been awarded the California state-wide fleet card contract by California's Department of General Services and the Office of Fleet and Asset Management. This multi-year contract was awarded based on Wex's technology, service and experience within the government space. The program will provide California state agencies and other eligible local government users convenient payment tools, reporting and analytics to support their purchasing of fuel, electric vehicle charging and other fleet-related expenses such as oil, fluids, lubricants, parts, repairs and maintenance.

06:46 EDT Sonoco Products increases prices 6% for paperboard tubes and cores - Sonoco will raise the price for all paperboard tubes and cores by a minimum of 6%, effective with shipments in the United States and Canada, on or after July 26.

06:34 EDT Alfi CEO says company 'undervalued based on pipeline projections' - In an 8-K filing, the the company states: "On June 22, 2021, a Benzinga news article was published based in part on an interview given by Paul Pereira, the CEO of Alfi. This Form 8-K is being furnished to provide certain information to investors that was stated in the article. The article stated that 'Alfi announced a new $2M buyback plan' and Mr. Pereira is quoted stating '[w]e will continue to buy back our stock as [a] firm commitment to our company valuation.' In addition, Mr. Pereira is quoted stating that Company's stock is 'undervalued based on pipeline projections and identified opportunity.' The article also contained statements from previous press releases from the company." Shares of Alfi are down over 10% in pre-market at $14.60 following yesterday's 109% gain.

06:33 EDT Quarterhill subsidiary enters license agreement with security solution provider - Wi-LAN, a Quarterhill company, announced that WiLAN's wholly-owned subsidiary, Security Video Camera Systems, or SVCS, has entered into a license agreement with a security video and solution provider. The license covers various security video technologies. The consideration payable to SVCS and all other terms of the license agreement are confidential.

06:27 EDT Cathie Wood's ARK Investment bought 192.9K shares of Splunk yesterday

06:26 EDT Cathie Wood's ARK Investment bought 214.7K shares of Coinbase yesterday

06:07 EDT Gravity's Ragnarok X: Next Generation game tops Apple App Store in SE Asia - Gravity (GRVY) announced that Ragnarok X: Next Generation, a MMORPG mobile game, has been officially launched in 9 countries within Southeast Asia on June 18, 2021 and the game has been ranked as the top of Apple (AAPL) App Store in Southeast Asia. When Ragnarok X: Next Generation was previously launched in Taiwan, Hong Kong and Macau on October 15, 2020, it ranked as the first in top grossing of Apple App Store and Google Play. More than 3 million accounts have been achieved in the pre-registration opened in Southeast Asia since April 23, 2021. The game ranked as the first in top grossing of Apple App Store in Thailand, Indonesia and the Philippines. It also exceeded 2 million downloads in Southeast Asia within 5 days after launching and sensational hit has been predicted in game market in Southeast Asia. Nuverse, a global game development and publishing company, publishes this game and Gravity Game Tech, Gravity's subsidiary in Thailand, supports the Nuverse as a joint publisher.

06:03 EDT IHS Markit CFO says 'we remain on track to deliver strong full year results' - "Our strong Q2 and first half results were in-line with our expectations and we remain on track to deliver strong full year results," said Jonathan Gear, CFO at IHS Markit.

06:02 EDT Amazon.com announces 14 new renewable energy projects - Amazon announced 14 new renewable energy projects in the U.S., Canada, Finland, and Spain to advance its ambitious goal to power 100% of company activities with renewable energy by 2025-five years ahead of the original target of 2030. The new projects bring Amazon's total renewable energy investments to date to 10 gigawatts of electricity production capacity-enough to power 2.5M U.S. homes. Amazon is now the largest corporate buyer of renewable energy in the U.S. and the world. The latest utility-scale solar and wind projects will supply renewable energy for Amazon's corporate offices, fulfillment centers, and Amazon Web Services data centers that support millions of customers globally. These projects will also help Amazon meet its commitment to produce enough renewable energy to cover the electricity used by all Echo devices in use. These new projects support hundreds of jobs while providing hundreds of millions of dollars of investment in local communities.

05:21 EDT BeiGene receives China NMPA approval for tislelizumab - BeiGene announced that the China National Medical Products Administration, or NMPA, has granted its anti-PD-1 antibody tislelizumab approval for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer, or NSCLC, and conditional approval for the treatment of patients with hepatocellular carcinoma who have been previously treated with at least one systemic therapy.

05:15 EDT Enanta reports EDP-721 preclinical data at EASL International Liver Congress - Enanta reported new preclinical data for EDP-721, a novel, oral hepatitis B virus, or HBV, RNA destabilizer being developed for use in an all-oral combination regimen for HBV. The data demonstrate selective and pangenotypic inhibition of HBV surface antigen, or HBsAg, with up to a three-log drop in the AAV-HBV mouse model. The research on EDP-721 was presented in a poster titled Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer, during the EASL International Liver Congress. EDP-721 was shown to be a selective inhibitor of the non-canonical polyA polymerases, PAPD5 and PAPD7, host factors critical to the post-transcriptional stabilization of HBV RNA. Inhibition of PAPD5/7 results in potent and pangenotypic reduction in HBsAg production with minimal effects on the host transcriptome in uninfected primary human hepatocytes. Oral administration of EDP-721 demonstrated HBsAg reductions of up to three logs following 14 days of once-daily dosing in the AAV-HBV mouse model. EDP-721 was also shown to exhibit synergistic antiviral activity in vitro when combined with nucleoside reverse transcriptase inhibitors or the HBV core inhibitor EDP-514. Enanta expects to initiate a Phase 1 single ascending dose and multiple ascending dose study to evaluate the safety and tolerability of EDP-721 in healthy volunteers in mid-2021.

05:10 EDT Sosei initiates HTL0022562 trial under Biohaven Pharmaceutical collaboration - Sosei Group announced that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562, or BHV3100, is a novel, small molecule CGRP receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical (BHVN) in December 2020 for development as new therapies for CGRP-mediated disorders. The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subjects. The trial aims to enroll 88 subjects at a single center in the UK and is expected to complete in 2022. Under the global collaboration and license agreement with Biohaven, Sosei Heptares will conduct the Phase 1 clinical trial itself, receiving a milestone payment for its initiation, and is also eligible for development costs for conducting the trial. Biohaven will lead all future studies and development activities and Sosei Heptares will be eligible for further milestone payments and royalties.

05:05 EDT Amgen gets Japanese Ministry of Health, Labour and Welfare approval for Aimovig - Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig for the suppression of onset of migraine attacks in adults. Aimovig is the first and only approved treatment in Japan to block the calcitonin gene-related peptide receptor, or CGRP-R, which is believed to play a role in migraine. This is also the first independent submission and approval for Amgen K.K., a wholly owned affiliate of Amgen headquartered in Tokyo.